1. Scrip
  2. >>Therapy Areas
  3. >>Dermatological

Ex-Novartis Exec Joins Checkpoint Agonist-Focused Biotech

Carolin Barth Is New CEO

 
• By Andrew McConaghie

The Oxford university spin-out MiroBio has a senior leadership team in place, and aims to have its first checkpoint agonists in the clinic in 2022. Scrip spoke to its CEO about its plans.

Oxford Science Park, Fletcher House and Winchester House
Miro Bio is headquartered at Oxford Science Park, UK

MiroBio, an emerging biotech focused on developing checkpoint agonist drugs has appointed Carolin Barth, former head of commercial and pipeline strategy, cell and gene therapy at Novartis, as its CEO.

The Oxford, UK-based company came out of stealth mode nearly two years ago with a $34m series A fundraising, and...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Dermatological

More from Therapy Areas

With ACIP Upheaval, Merck & Co. Among Those Left In A Lurch

 
• By Jessica Merrill and Bridget Silverman

Merck’s newly approved Enflonsia for RSV is one of the products that was expected to be recommended for use by the CDC advisory committee in June.

Stock Watch: On Q1 Vaccine Sales And Measles Outbreaks

 
• By Andy Smith

A recent study suggested that measles could become endemic in the US due to low vaccination rates. However, first-quarter vaccine sales offered a more nuanced picture.

Metsera’s Amylin Analog Stars In Obesity Phase I

 
• By Joseph Haas

Intended as obesity monotherapy and for combination with the firm’s GLP-1 analog, MET-0233i showed best-in-class efficacy with placebo-like tolerability at low doses.